Delafloxacin

Drug Profile

Delafloxacin

Alternative Names: ABT-492; Baxdela; RX-3341; WQ-3034

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Wakunaga Pharmaceutical
  • Developer Abbott Laboratories; Melinta Therapeutics
  • Class Antibacterials; Azetidines; Fluoroquinolones; Pyridines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Skin and soft tissue infections
  • Phase III Community-acquired pneumonia
  • Phase I Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections
  • Discontinued Acute exacerbations of chronic bronchitis; Anthrax; Gonorrhoea

Most Recent Events

  • 05 Jan 2017 PDUFA action date of 19/06/2017 assigned by FDA for delafloxacin for Skin and soft tissue infections (IV, PO)
  • 01 Dec 2016 Phase-III clinical trials in Community-acquired pneumonia in USA (IV) (NCT02679573)
  • 26 Oct 2016 Safety and efficacy data from the phase III RX3341-303 trial in Skin and soft tissue infections were presented at the IDWeek-2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top